St. Jude

Two new analyses have identified driver genes, altered pathways, mutational signatures, and other molecular features across two dozen cancer subtypes.

A proportion of pediatric ALL patients appear to have germline TP53 mutations associated with later diagnoses, poorer outcomes, and increased secondary cancer risk.

Right Patient Right Drug will use the PharmacoScan platform to perform preventive pharmacogenetic testing under St. Jude's PG4KDS program.  

Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.

Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.

Suspicious variants were uncovered through analyses of pediatric cancer survivors from the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study.